Lonza and BioOne to build biopharma plant in Singapore
Switzerland's Lonza and Singapore's BioOne Capital have formed a joint venture in Singapore for the production of biopharmaceuticals.
Switzerland's Lonza and Singapore's BioOne Capital have formed a joint venture in Singapore for the production of biopharmaceuticals.
A plant is to be built that will include four mammalian bioreactor trains each with a flexible capacity of 1,000 up to 20,000 litres and inclusive of the respective purification units.
The plant will be built in two phases: construction of the plant shell will commence at the end of 2005; and the final build-out will be finished within 24 months of the completion of the shell.
BioOne Capital is a biomedical sciences investment management company, which focuses on Asia and this project represents a further investment in biopharmaceutical manufacturing for the company.
Lonza already operates 18 production and r&d sites around the world and is a leading custom manufacturer of chemical intermediates and active ingredients as well as biopharmaceuticals for the pharmaceutical and agrochemical industries.